| 查看: 1790 | 回复: 101 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
|
|||
|
Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。 相关阅读： Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.” Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.” Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
回复此楼» 猜你喜欢
本人考085602 化学工程 专硕
已经有23人回复
-
求调剂院校信息
已经有4人回复
-
085600材料与化工306
已经有4人回复
-
286求调剂
已经有10人回复
-
328求调剂，英语六级551，有科研经历
已经有9人回复
-
一志愿北京化工大学070300 学硕336求调剂
已经有4人回复
-
286分人工智能专业请求调剂愿意跨考！
已经有8人回复
-
资源与环境 调剂申请(333分)
已经有5人回复
-
280求调剂
已经有12人回复
-
269专硕求调剂
已经有5人回复
» 抢金币啦！回帖就可以得到:
-
天津理工大学国家杰青王铁课题组招收2026年博士研究生
+1/82
-
浙江农林大学招收调剂
+1/78
-
有没有在香港的虫友啊
+1/72
-
坐标广州，男征女，双向奔赴
+1/66
-
武汉高校接受研究生调剂，材料、化学、纺织方向
+2/46
-
江苏科技大学能源材料化学课题组郭兴梅教授招收博士研究生1-2名
+1/46
-
湘潭大学“过程强化与绿色化工”创新团队补招2026年秋入学博士生
+1/35
-
中国科学院杭州医学研究所覃江江课题组招聘博士后
+1/30
-
双一流湘潭大学化工学院招收化工、能源动力、工程热物理相关研究生调剂
+1/20
-
重庆文理学院化学与环境工程学院 2026 届硕士研究生调剂通知
+1/13
-
计算机(11408)考研361分求调剂
+1/13
-
南昌一本市政工程接受调剂
+1/12
-
多伦多大学 & Synetic Labs 招博士后/研究员
+1/8
-
【博士招生】武汉科技大学招收材料、化工、环境、冶金类2026年“申请-考核”制博士生
+1/7
-
新加坡国立大学药学系化学生物学课题组招PhD
+1/6
-
【第三轮招生】澳科大诚招2026年秋季药剂学硕士研究生（3月31日下午18:00截止）
+1/5
-
双一流天津工业大学电信学院李鸿强教授招收2026年申请审核制博士3名
+1/3
-
东北林业大学（211，双一流）宋老师课题组招收高分子、化学、复合材料等方向研究生
+1/2
-
“机械、材料”招生
+1/1
-
昆明理工大学陈江照教授团队博士招生
+1/1
83楼2015-11-20 16:21:10
简单回复
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
江南的竹10楼
2015-11-20 15:58
回复
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
